case / 18 Aug 2021
Setterwalls has assisted SwissHealth Ventures, as co-lead investor with several international VC investors in the Swedish based start-up Flow Neuroscience offering a new treatment method for depression
Setterwalls has assisted SwissHealth Ventures, a member of the CSS Group, Switzerland’s leading health insurer, as co-lead investor with the investment in the Swedish based med-tech company Flow Neuroscience along with the Silicon Valley VC firm Khosla Ventures and Swizz Zühlke Ventures.
In the USD 9M investment, joined also Japanese Kirin Holdings (in beverages and pharmaceutical products) led by the Japanese VC firm Global Brain, the US VC firm SOSV’s early stage investor HAX, as well as the San Francisco based patent firm Schox.
Flow Neuroscience has developed a new digital medication-free depression treatment which combines an easy-to-use brain stimu¬lation headset with a personalized therapy mobile app. This enables patients to treat depression under guidance at home or in the company of a specialist. The treatment is regulatory approved in i.a. the EU and UK.